Download - 13 liver cancer
![Page 1: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/1.jpg)
Department of Hepatobiliary Oncology,SYSUCC
Anti-liver cancer team
Shengping Li, M.D., Ph.D
![Page 2: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/2.jpg)
•Advanced stage
•Low resection rate
•High recurrence
•Decompensation liver function
Poor prognosisFierce
![Page 3: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/3.jpg)
Liver cancer
PLC (Primary Liver Cacner)
Secondary Liver Cancer
HCC(Hepatocellular carcinoma)
CCC(Cholangiocellular carcinoma)
HCC
HCC and CCC mixed
![Page 4: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/4.jpg)
Epidemiology
“Hot spots” – 150 per 100 000
US, Australia : 2 per 100 000
•The fifth most common
cancer worldwide
•CA Cancer J Clin 2005
![Page 5: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/5.jpg)
High incidence In China
• Shanghai
• Jiangsu
• Fujiang
• Guangdong
• Guangxi
Epidemiology
![Page 6: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/6.jpg)
Trend of Death rate of malignant Trend of Death rate of malignant tumor in China tumor in China
LungLiverStomach
1282004-2005
StomachLiverLung
1061990-1992
Stomach EsophagusLiver
801973-1974
Three leading causes of Ca. death
Death Rate(per100,000)
Period(years)
![Page 7: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/7.jpg)
EtiologyEtiology
Hepatitis
Alcoholism
Environmental factors
molecular and Cytogenetic alterations
![Page 8: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/8.jpg)
HBV 80% (Asia and Africa),
100 million china
HCV 70% (Japan,West count
ries)
Hepatitis virus infectionHepatitis virus infection
![Page 9: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/9.jpg)
Alcoholism: alcoholic cirrhosis
![Page 10: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/10.jpg)
Food contaminated with aflatoxin
Decayed peanut,corn
Turkey Liver cancer
![Page 11: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/11.jpg)
Liver Flukes (Clonorchis sinensis )
![Page 12: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/12.jpg)
Liver Flukes InfestationLiver Flukes Infestation
![Page 13: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/13.jpg)
Mutation of oncogene and tu
mor suppressor gene
(癌基因和抑癌基因的突变) N-ras,c-myc,cfms,CSF-1R, IGF
-II , p53 , TTR, DLC-1, LPTS, W
FDC1, HCCS1, HCRP1, 17HSDB2
Chromosomal alterations
( 染色体改变)
Gain (获得) :1q,8q and 20q
Lose (缺失) : 4q,8p,13q,16q
,
and 17p
( Li SP, et al . J Hepatology 2001)
Molecular and cytogenetic aberration
(分子和细胞遗传学变异)
![Page 14: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/14.jpg)
Peoples lived in high incidence of liver cancer area
Peoples persistent infection of hepatitis virus
Family history of liver cancer
Liver cancer history previously
High Risk Group
![Page 15: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/15.jpg)
Early stage Subclinical stage
Non symptom and sign
Clinical manifestation
![Page 16: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/16.jpg)
• Abdominal pain and distention
• Weight loss
• Hepatomegaly : 80%
• Abdominal mass
• Jaundice ,ascites
Clinical stage
![Page 17: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/17.jpg)
Diagnosis of HCCDiagnosis of HCC
Serological (tumor markers)
Radiological
Cytological
Histological
Either alone or in combination
![Page 18: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/18.jpg)
Tumor markers for HCCTumor markers for HCCMost common used
![Page 19: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/19.jpg)
Diagnostic Imaging for Diagnostic Imaging for HCCHCC
![Page 20: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/20.jpg)
Radiology--USRadiology--US
Ultrasound– Availability, cost– Operator
dependant– Therapeutic role.
![Page 21: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/21.jpg)
Radiology--CTRadiology--CT
Triphasic CT – detect 30 – 40%
more tumour nodules than conventional CT.
Lipiodol – Retained by all
hypervascular liver tumours.
![Page 22: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/22.jpg)
Radiology--MRIRadiology--MRI
Slightly higher sensitivity than CT in detecting hepatic lesions.
Cost, availability.
![Page 23: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/23.jpg)
Diagnosis and treatment simultaneously
Invasive, not routinely used
Radiology--angiographRadiology--angiograph
![Page 24: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/24.jpg)
• Expensive
• Whole body sca
ning
• Tumor cell Funct
ion
Radiology--Positron Emission computed Tomography, PET/CT
![Page 25: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/25.jpg)
Liver BiopsyLiver Biopsy
Biopsy now rarely required to diagnose HCC.
Avoid biopsy of potentially resectable tumour.– Risk of needle track seeding 1 – 3%– Risk of bleeding
![Page 26: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/26.jpg)
US and CT most commonly used clinically
Diagnostic imaging for Diagnostic imaging for HCCHCC
![Page 27: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/27.jpg)
1. AFP≥400 ng/L, palpable mass or space-occupying
lesions in the liver by imaging
2. AFP<400 ng/ L, specific liver cancer images confir
med by at least two kinds of imaging scanning
3. Clinical manifestation of liver cancer with patholog
ical diagnosed extrahepatic liver cancer and meta
stases liver tumor ruled out
Standard rule for Diagnosis of HCC
![Page 28: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/28.jpg)
Clinical Application of Clinical Application of AFPAFP
1.Screening of liver cancer
2.Dianosis of liver cancer
3.Predicting prognosis after treatment
4.Surveillance of recurrence after
treatment( decrease to normal level
within 1-2 months after resection)
![Page 29: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/29.jpg)
Differential diagnosisDifferential diagnosis
AFP positive
chronic active hepatitis, cirrhosis, testicular tumor,
pregnancy
AFP negative
haemangioma, metastatic liver carcinoma, absces
s, focal nodular hyperplasia (FNH), hepatic hydatid
osis
![Page 30: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/30.jpg)
Pregnancy with HCC
Delivery baby and resection of HCC simultaneously
![Page 31: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/31.jpg)
Hepatic haemangioma
![Page 32: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/32.jpg)
Colon cancer liver Colon cancer liver metastasismetastasis
![Page 33: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/33.jpg)
Focal Nodular Hyperplasia Focal Nodular Hyperplasia (FNH)(FNH)
![Page 34: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/34.jpg)
Hepatic AbscessHepatic Abscess
![Page 35: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/35.jpg)
Hepatic Hepatic HydatidosisHydatidosis
![Page 36: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/36.jpg)
![Page 37: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/37.jpg)
Therapeutic Option for Therapeutic Option for HCCHCC
![Page 38: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/38.jpg)
SurgerySurgery
Langenbuch 1888 first left hepatic
lobectomy Tiffany 1890
first liver resection for solid tumour
Starzl 1963 first liver
graft
![Page 39: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/39.jpg)
Principles of Surgical Principles of Surgical ManagementManagement
Determining resectability
Stage of tumour
Functional hepatic reserve
80%-90% of HCC occur in cirrhotic livers
Less than 20% of patients with HCC are candidates for resection at time of presentation.
![Page 40: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/40.jpg)
1. Staging1. Staging
TNM– Stage III, IV unresectable
Okuda CLIP (Cancer of the Liver Italian Program) Barcelona Staging Classification
– Performance scores, Okuda, tumour morphology
French Staging Classification– Performance scores, LFT, US
![Page 41: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/41.jpg)
TNM Staging System
![Page 42: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/42.jpg)
stagingstaging
Because the combined impact of liver diseaseand tumor burden is not yet fully understood, andthe cause of HCC may vary geographically, noneof the currently used staging systems fulfils all therequirements for stratification of patients with HCCinto groups of different prognosis and therapeuticrecommendations. None of the staging systems isuniversally accepted.
![Page 43: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/43.jpg)
2. Functional Reserve2. Functional Reserve
Resection only of benefit in patients with adequate functional reserve.
Assessment of liver function : – Synthetic capacity of liver
» Serum albumin, prothormbin time
– Excretion of metabolites» Indocyanine dye test, bilirubin, bile acid profile
– Child-Pugh Classification
![Page 44: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/44.jpg)
Child Pugh ClassificationChild Pugh Classification
![Page 45: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/45.jpg)
2. Functional Reserve2. Functional Reserve
Portal hypertension Estimation of likely remaining liver
volume after resection Comorbidities
– ASA / Performance scores– Nutritional state : Perioperative
nutritional support decreases post operative morbidity
![Page 46: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/46.jpg)
5-year survival 26-50%, mean 30%
5 years recurrence rate is about 70%
A critical clinical problem
Hepatectomy
![Page 47: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/47.jpg)
6 mPre-op
![Page 48: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/48.jpg)
Cutting edge recurrence
![Page 49: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/49.jpg)
Liver transplantationLiver transplantation
• Potentially resect HCC while replacing the cirrhotic liver
• Milan criteria for HCC
Single lesion <5cm or upto three lesions <3cm
![Page 50: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/50.jpg)
LimitationLimitation
Immunosuppression– Recurrent hepatitis– Recurrent HCC
Shortage of donors – Consider “bridging therapy” to
prevent tumour progression.– Living donors
![Page 51: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/51.jpg)
Non Surgical Management Non Surgical Management Transcatheter Arterial Chemoembolization Percutaneous microwave coagulation therapy Percutaneous ethanol injection Radiofrequency Ablation Cryosurgery Systemic Chemotherapy Hormonal therapy Immunotherapy Gene Therapy Chinese medicine
![Page 52: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/52.jpg)
Percutanous interventiPercutanous interventiononPEI: percutanous ethanol injection
RF: Radiofrequency ablation
MCT: microwave coagulation thermotherapy
LT: Laser thermotherapy
Cryoablation
Best option for small unresectable HCC
![Page 53: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/53.jpg)
将 10枚象“弹头”一样的小电极通过穿刺针管送入癌组织,多枚小电极从不同的角度和方向“锁定”癌症组织区域,由计算机测算出射频治疗所需的最佳温度,时间,功率和阻抗,由小电极发出高能射频波,在 100
—120℃的高温下,使癌组织蛋白发生凝固性坏死,达到杀灭癌组织的效果。
3.5cm/15G 10 electrodes Lee Veen needle
![Page 54: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/54.jpg)
Radiafrequency ablation,RF•Alternative to PEI
•Applied percutaneously,laparoscopically, during laparotomy
•Expensive but offer a better local control
•Ablation of tumor large than 5 cm in diameter
![Page 55: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/55.jpg)
![Page 56: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/56.jpg)
• The most widely used treatments for HCCs which
are unresectable or cannot be effectively treated with
percutaneous interventions.
•Embolization agents: Lipiodol,gelfoam
•Chemotherapeutics: doxorubicin, 5-Fu, mitomycin, cisplatin
•Partial responses in 15-55% of patients
• Delays tumor progression and vascular invasion
•Prolongs the survival time compared to conservative management.
TACE or TAE
![Page 57: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/57.jpg)
TACE or TAE
•Patients liver function Child A
•Without vascular invasion or extrahepatic spread.
•Advanced liver disease (Child B or C), treatment-induced liver failure may offset the antitumor effect or survival benefit of the intervention.
•Postoperative adjuvant TACE may improve survival in patients with risk factors for residual tumor
![Page 58: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/58.jpg)
Tumor shrinkage post-TACE
![Page 59: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/59.jpg)
Principles of
management •Treatment in early stage
•Combination therapy
•Actively( time and again)
![Page 60: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/60.jpg)
Metastasis of HCC
Intrahepatic ---port vein pathway, satellite
Extrahepatic: lung Lymphatic pathway: CCC Invasion periheaptic organs directly Abdominal implantation: tumor rupture
![Page 61: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/61.jpg)
HCC metastasis
![Page 62: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/62.jpg)
Continuing challenges
•Prevalance of chronic hepatitis
•Low resection rate
•High recurrence rate post-resection
•Shortage of liver donor
•Optimal combination therapy
•Molecular staging system
![Page 63: 13 liver cancer](https://reader036.vdocuments.us/reader036/viewer/2022062300/5564b764d8b42a98268b5377/html5/thumbnails/63.jpg)
Thank you!Thank you!